UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
|
|
- Myra Summers
- 5 years ago
- Views:
Transcription
1 Updates in the Management of Atrial Fibrillation Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic UC SF Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE Atrial Fibrillation Most common clinically significant cardiac arrhythmia Affects ~ 2.2 million people in the US Prevalence will rise as the population ages ~1 in 4 lifetime risk for patients older than 40 years Responsible for 15-20% of strokes Objectives Rate vs. rhythm control Overview of antiarrhythmic strategies Risk stratification for stroke and antithrombotic treatment Newer anticoagulants Goals of Therapy in Patients With AF Prevention of stroke (thromboembolism) Prevention of tachycardia-induced cardiomyopathy Symptom relief Primary prevention of other cardiovascular events 1
2 Treatment Strategies for AF Which of the following is most true? Rate Control Pharmacologic Ca 2+ blockers β-blockers Digitalis Amiodarone Nonpharmacologic Ablate and pace Prevent Remodeling Pharmacologic Antiarrhythmic drugs: Class IA Class IC Class III Maintenance of SR a CCB ACE-I, ARB Statins Nonpharmacologic Catheter ablation Pacing Surgery Implantable devices Stroke Prevention Pharmacologic Aspirin Thrombin inhibitor Nonpharmacologic Removal/isolation LA appendage a Consider for symptomatic patients 1. Rhythm control with antiarrhythmic medications is superior to rate control 2. Rhythm control with cardioversion + antiarrhythmic medications is superior to rate control 3. Rate control is superior to rhythm control 4. Rate control and rhythm control have similar outcomes Prystowsky EN. Am J Cardiol Rate vs. Rhythm Rhythm control not superior to rate control No differences in stroke rates or quality of life Stroke rates: 5.5% with rate control and 7.1% with rhythm control (p=0.79) Does not obviate need for anticoagulation Stroke events occurred mostly in patient off or sub- therapeutic on warfarin, regardless of rhythm Trend towards worse outcomes with rhythm control, probably due to drug toxicity Rate Control Should be part of initial therapy for AF Beta-blockers or nondihydropyridine calcium channel blockers are first-line agents Digoxin may be helpful in those with heart failure, who are sedentary, or as a 2 nd drug AV node ablation can be considered if drug therapy fails AFFIRM Investigators, NEJM
3 Strict vs. Lenient Rate Control Strict rate-control (resting heart rate < 80 bpm) had similar outcomes compared to lenient rate-control (resting heart rate < 110 bpm) No difference in cardiovascular death, heart failure, stroke, bleeding, arrhythmias: 14.9% in strict and 12.9% in lenient Strict rate-control may not be beneficial unless heart rate symptomatic Which of the following is most true? 1. Rhythm control with antiarrhythmic medications is superior to rate control 2. Rhythm control with cardioversion + antiarrhythmic medications is superior to rate control 3. Rate control is superior to rhythm control 4. Rate control and rhythm control have similar outcomes Van Gelder et al, NEJM 2010 Which of the following is most true? 1. Rhythm control with antiarrhythmic medications is superior to rate control 2. Rhythm control with cardioversion + antiarrhythmic medications is superior to rate control 3. Rate control is superior to rhythm control 4. Rate control and rhythm control have similar outcomes Rhythm Control Rhythm control recommended for symptomatic atrial fibrillation Can consider cardioversion with new onset atrial fibrillation Most effective when initiated close to atrial fibrillation onset Antiarrhythmic medications Catheter ablation 3
4 Which of the following antiarrhythmics is considered first-line therapy for patients with AF and heart failure? 1. Flecainide 2. Sotalol 3. Amiodarone 4. Dronedarone Antiarrhythmic Drugs Drug choice depends on clinical comorbidities and side-effect effect profile Class IC agents (flecainide, propafenone) amiodarone, sotalol, and dronedarone can be started as outpatients in patients with minimal underlying heart disease Pill in the pocket approach for paroxysmal atrial fibrillation Amiodarone probably the most effective agent but limited by side-effectseffects Preferred antiarrhythmic in patients with heart failure Dronedarone New antiarrhythmic approved in 2009 Less effective than amiodarone, but may have somewhat fewer side-effectseffects Avoid in patients with heart failure Drug-drug interactions Digoxin, statins QT interval prolongation or CYP3A4 inducers May potentiate nodal blockade when used with beta- blockers/calcium channel blockers Case reports of hepatotoxicity; should monitor LFTs during initiation of therapy Catheter Ablation May be useful for symptomatic atrial fibrillation or if antiarrhythmic medications do not control rhythm Outcomes are not well described for older patients or those with heart failure Many people go back into atrial fibrillation Highest relapse rate is within the first year Piccini et al, JACC 2009; 2011 ACCF/AHA/HRS Guidelines 4
5 Sinus Rhythm after First Catheter Ablation Maintenance of Sinus Rhythm No Heart Disease HTN CAD CHF Patients in Sinus Rhythm (%) Weerasooriya et al. JACC % 29% Amiodarone Dofetilide Dronedarone Flecainide Propafenone Sotalol Catheter Ablation No LVH? Yes Amiodarone Dofetilide Dronedarone Sotalol Amiodarone Dofetilide Catheter Ablation 2011 ACCF/AHA/HRS Practice Guidelines Which of the following antiarrhythmics is considered first-line therapy for patients with AF and heart failure? 1. Flecainide 2. Sotalol 3. Amiodarone 4. Dronedarone Which of the following antiarrhythmics is considered first-line therapy for patients with AF and heart failure? 1. Flecainide 2. Sotalol 3. Amiodarone 4. Dronedarone 5
6 A 70 y/o man presents with atrial fibrillation. He has a history of hypertension, asthma, peripheral arterial disease, and diabetes. What is his CHADS2 stroke risk score? 1. CHADS2 = 1 2. CHADS2 = 2 3. CHADS2 = 3 4. CHADS2 = 4 5. CHADS2 = 5 CHADS 2 Risk Scheme For Stroke Risk Factors Score C Recent congestive heart failure 1 H Hypertension 1 A Age 75 years 1 D Diabetes mellitus 1 S 2 History of stroke or transient ischemic attack (TIA) 2 Gage et al., JAMA 2001 CHADS 2 Risk Score and Stroke Rates CHADS 2 Score Stroke Rate per 100 p-yrs A 70 y/o man presents with atrial fibrillation. He has a history of hypertension, asthma, peripheral arterial disease, and diabetes. What is his CHADS2 stroke risk score? 1. CHADS2 = 1 2. CHADS2 = 2 3. CHADS2 = 3 4. CHADS2 = 4 5. CHADS2 = 5 Gage et al., JAMA, Rates from NRAF Cohort Study 6
7 A 70 y/o man presents with atrial fibrillation. He has a history of hypertension, asthma, peripheral arterial disease, and diabetes. What is his CHADS2 stroke risk score? 1. CHADS2 = 1 2. CHADS2 = 2 3. CHADS2 = 3 4. CHADS2 = 4 5. CHADS2 = 5 Stroke Risk Low (<1%/yr) Intermediate (1-4%/yr) High (>4%/yr) 8 th ACCP Guidelines CHADS2 = 0 CHADS2 = 1 CHADS2 2 Recommended Treatment Aspirin 75 to 325 mg or Aspirin 8 th ACCP Consensus Statement, Chest The most commonly used oral anticoagulant Reduces risk of atrial fibrillation-related related stroke by 64% Recommended International Normalized Ratio (INR) range: works but what about bleeding? Hart et al, Ann Intern Med
8 Falls and Intracranial Hemorrhage Relatively little data on falls and ICH Oldest patients generally excluded from studies Some observational data: Fall Risk ICH Rate Stroke Rate High 2.8% 13.7% Not high 1.1% 6.9% Gage et al, Am J Med Falls and Intracranial Hemorrhage Assessed effect of warfarin on combined outcome of stroke, major hemorrhage, MI in patients at high fall risk CHADS 2 HR [95%CI] Recommended Treatment [ ] Aspirin or none [ ] 0.9] Anticoagulation Moderate and high stroke risk warfarin Gage et al, AJM, You start your patient on warfarin. Over the next 6 months however, his INRs have been difficult to control. He wants to know whether he can stop warfarin. What do you recommend? 1. Stop warfarin and start aspirin 2. Stop warfarin and start aspirin + clopidogrel 3. Stop warfarin and start dabigatran 4. Obtain genetic testing to help figure out his optimal dose and advise him to continue warfarin Genotype-guided Dosing Two haplotypes related to warfarin response CYP2C9 (cytochrome P450 enzyme, which metabolizes warfarin) VKORC1 (Vitamin K epoxide reductase complex, required to regenerate vitamin K) dosing algorithms using genotyping + clinical factors can predict 50-60% of the variability in warfarin dosing However, not yet clear whether incorporating genetic testing significantly improves patient outcomes International Pharmacogenetics Consortium, NEJM
9 Alternatives to? Antiplatelet agents Direct thrombin inhibitors Factor Xa inhibitors Aspirin Compared to placebo, aspirin reduces stroke risk by 22% Considerably less effective than warfarin BAFTA Trial: randomized older patients (mean age 81.5 years) to warfarin vs. aspirin more effective Bleeding rates were similar (1.4% per year on warfarin, 1.6% on aspirin) Hart et al, Ann Intern Med 2007; Mant et al, Lancet 2007 Clopidogrel + Aspirin Less Effective than for Stroke Prevention Aspirin + Clopidogrel More Effective Than Aspirin Alone in Non- Candidates Cumulative Hazard Rates RR = 1.72 ( ) Clopidogrel + aspirin Oral anticoagulation therapy 0.5 Years Cumulative Hazard Rates HR = 0.72 ( ) Aspirin Clopidogrel + aspirin Years ACTIVE-W Trial, Connolly S, et al. Lancet ACTIVE A Trial: Connolly SJ, et al. NEJM
10 New and Investigational Agents for Stroke Prevention in AF Direct thrombin inhibitors Dabigatran (RE-LY): FDA approved for prevention of stroke and blood clots in patients with AF (10/19/10) Direct factor Xa inhibitors Rivaroxaban (ROCKET AF) Apixaban (ARISTOTLE) Edoxaban (ENGAGE-AF) AF) Betrixaban (EXPERT) YM150 (ONYX-2) Indirect Xa inhibitors Idraparinux (BOREALIS-AF) AF) Indirect inhibitors (eg, odiparcil) New and Investigational Agents Mechanisms Intrinsic pathway XII XI IX VIII X V II Fibrinogen Fibrin clot VII Extrinsic pathway Tissue factor Direct FXa inhibitors (rivaroxaban, apixaban) Direct thrombin inhibitors (dabigatran) Newer Anticoagulants Target Time to effect Dabigatran Rivaroxaban Apixaban Thrombin Factor Xa Factor Xa 2 hrs hrs 3 hrs Half-life hrs 9-13 hrs (older pts) Monitoring Administration Not needed Twice daily Not needed Once daily 8-15 hrs Not needed Twice daily Bioavailability 5%-6% 60%-80% 50%-85% Renal excretion 80% 33% 25% Drug interactions PPI and P-gp inhibitors Potent CYP3A4 inhibitors Potent CYP3A4 inhibitors RE-LY Trial: Dabigatran vs. Dabigatran 110 mg (n = 6015) Annual Rate Dabigatran 150 mg (n = 6076) Annual Rate (n = 6022) Annual Rate Stroke 1.4% 1.0% 1.6% Death 3.8% 3.6% 4.1% Dabigatran 110 mg vs RR 95% CI P Value Dabigatran 150 mg vs RR 95% CI P Value < Connolly SJ, et al N Engl J Med
11 Dabigatran vs. Dabigatran 110 mg Annual Rate Dabigatran 150 mg Annual Rate Annual Rate Major Bleeds 2.7% 3.1% 3.4% Intracranial Hemorrhage 0.2% 0.3% 0.7% Myocardial Infarction 0.7% 0.7% 0.5% Dabigatran 110 mg vs Dabigatran 150 mg vs RR 95% CI P Value.003 < RR 95% CI P Value < Dabigatran At least similar in efficacy to warfarin for AF May have lower rates of intracranial hemorrhage Associated with a slight increase in risk of myocardial infarction FDA approved doses: 150mg BID and 75mg BID dosing (for CrCl < 30) More costly than warfarin No way to monitor or reverse anticoagulant effect Connolly SJ, et al N Engl J Med When Should I Prescribe Dabigatran? Patients who have difficulty remaining in a therapeutic INR range on warfarin Do not have renal insufficiency Can be adherent to twice a day dosing Can afford dabigatran ROCKET-AF Trial: Rivaroxaban vs. Vascular death, stroke, embolism Ischemic stroke Intracranial hemorrhage Rivaroxaban 20mg (n = 7081) Annual Rate (n =7090) Annual Rate Major bleeding Rivaroxaban vs. RR 95% CI 0.86 ( ) 0.99) 0.94 ( ) 0.67 ( ) 0.94) 1.04 ( ) P Value Califf R. Presented at: American Heart Association Scientific Sessions
12 Rivaroxaban Similar efficacy and safety compared to warfarin Not yet approved for use in the US Once daily dosing Hepatically-cleared cleared (might be able to use in renal insufficiency) Also no effective way to monitor or reverse anticoagulant effect You start your patient on warfarin. Over the next 6 months however, his INRs have been difficult to control. He wants to know whether he can stop warfarin. What do you recommend? 1. Stop warfarin and start aspirin 2. Stop warfarin and start aspirin + clopidogrel 3. Stop warfarin and start dabigatran 4. Obtain genetic testing to help figure out his optimal dose and advise him to continue warfarin You start your patient on warfarin. Over the next 6 months however, his INRs have been difficult to control. He wants to know whether he can stop warfarin. What do you recommend? 1. Stop warfarin and start aspirin 2. Stop warfarin and start aspirin + clopidogrel 3. Stop warfarin and start dabigatran 4. Obtain genetic testing to help figure out his optimal dose and advise him to continue warfarin Summary Rate control and rhythm control have similar outcomes May not require strict rate control Consider rhythm control for symptomatic patients Choice of therapy depends on patient characteristics and side- effect profile Antithrombotic therapy should be guided by risk stratification is more effective than antiplatelet agents Net benefit of warfarin increases with older patients at higher stroke risk Newer anticoagulants (dabigatran, rivaroxaban) may become viable alternatives to warfarin 12
13 Bibliography Thank you! 1. AFFIRM Investigators: A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. New England Journal of Medicine 2002; 347(23): Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: Gage BF, Birman-Deych E, Kerzner R, Radford M, Nilasena DS, Rich MW: Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. American Journal of Medicine 2005; 118: Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): Hart R, Pearce LA, Aguilar MI: Meta-analysis: analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine 2007; 146: Hohnloser SH, Crijns HJGM, van Eickels M, et al.: Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine 2009; 360(7 ): Mant J, Hobbs R, Fletcher K, et al.: versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370(9586): Bibliography Bibliography 8. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF: Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. J Am Coll Cardiol 2009; 54(12): Prystowsky EN: Management of atrial fibrillation: therapeutic options and clinical decisions. American Journal of Cardiology 2000; 85(10, Supplement 1): ROCKET AF Study Investigators: Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. American Heart Journal 2010; 159(3): Singer DE, Albers GW, Dalen JE, et al.: Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6_suppl): 546S Singer DE, Chang Y, Fang MC, et al.: The Net Clinical Benefit of Anticoagulation in Atrial Fibrillation. Ann Intern Med 2009; 151(5): Singer DE, Chang Y, Fang MC, et al.: Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study. Circ Cardiovasc Qual Outcomes 2009; 2(4): The ACTIVE Investigators: Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine 2009; 360(20 ): The ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al.: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367(9526): The International Pharmacogenetics Consortium: Estimation of the Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine 2009; 360(8 ): Van Gelder IC, Groenveld HF, Crijns HJGM, et al.: Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. New England Journal of Medicine; 362(15 ): Wann LS, Curtis AB, January CT, et al.: 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123(1): Weerasooriya R, Khairy P, Litalien J, et al.: Catheter Ablation for Atrial Fibrillation: Are Results Maintained at 5 Years of Follow-Up? J Am Coll Cardiol 2011; 57(2):
NeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationConflicts of Interests
Advances in the Management of Atrial Fibrillation State of the Art in 2013 Overview of AF Stroke risk and anticoagulation Rate control Antiarrhythmic Drug Therapy Catheter ablation Conclusion Hugh Calkins
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More information:{ic0fp'16. Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines. (and the Evidence for When to Stray) Kevin Overbeck, DO
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines (and the Evidence for When to Stray) Kevin Overbeck, DO Optimal Heart Health
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationAtrial Fibrillation in the Elderly: Causes, Symptoms, and Treatment
Atrial Fibrillation in the Elderly: Causes, Symptoms, and Treatment Asa Oxner, MD Assistant Professor of Medicine Division of General Internal Medicine University of South Florida Co-Investigator: Geriatric
More informationObjectives for Technicians. Objectives for Pharmacists. Pathophysiology. Conflict of Interest. Atrial Fibrillation
Warfar IN or Warfar-OUT? And Other Updates in the Management of Atrial Fibrillation Kimberly Ackerbauer, PharmD, BCPS Clinical Pharmacy Specialist Rush University Medical Center Conflict of Interest I
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationAtrial Fibrillation Management in the ED. J Fisher May 2014"
Atrial Fibrillation Management in the ED J Fisher May 2014" A 48 yr old man presents with palpitations. He had a big night last night with old mates. ECG How will you manage him? Why important? Common
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationModest Medtronic. Modest Boehringer Ingelheim
Adults With AF (millions) Modest Medtronic Modest Boehringer Ingelheim Changing Modalities of Care for Atrial Fibrillation Jill Repoley MSN, CRNP, CCDS, CEPS, FHRS 7 6 5 4 3 2 1 2.08 2.26 2.44 2.66 2.94
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationFred Kusumoto Professor of Medicine
Fred Kusumoto Professor of Medicine Faculty photo will be placed here Kusumoto.Fred@mayo.edu 2015 MFMER 3543652-1 Atrial Fibrillation Presentation Subtitle Here Mayo School of Continuous Professional Development
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationWarfarin Management-Review
Warfarin Management-Review December 18, 2012 Elaine M. Hylek, MD, MPH Director, Thrombosis Clinic and Anticoagulation Service Boston University Medical Center Areas for Discussion Implications of time
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationManagement of Atrial Fibrillation in 2013
Management of Atrial Fibrillation in 2013 No financial disclosures Katherine Julian, MD August 9, 2013 Epidemiology Most common arrhythmia in clinical practice 2.3 million people in North America Average
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationManagement of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim
a holistic view - Prof. Dr. Martin Borggrefe Mannheim Patients with atrial fibrillation (millions) 16 14 12 10 8 6 4 2 0 Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationInitial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care
Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care 11 th and 25 th September 2014 3 KEY OBJECTIVES OF TALK 1.
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More information